| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2025―Jul―03 |
Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma under-diagnosis and delayed care? |
Dimitrios Karponis, Khaylen Mistry, Giannis Stratigos, Nick J Levell, Alexander J Stratigos, Vasiliki Nikolaou, Zoe C Venables |
| 2 |
[GO] |
2025―Jun―27 |
P074 Pemphigus vulgaris management after COVID-19: challenges of low- and middle-income countries |
Amna Khalid, Atiya Rahman |
| 3 |
[GO] |
2025―Jun―27 |
P108 Association between COVID-19 vaccines and bullous pemphigoid: a UK population-based study |
Mikolaj Swiderski, Yana Vinogradova, Matthew J Ridd, Zenas Z N Yiu, Antonia Lloyd-Lavery, Vibhore Prasad, Sonia Gran |
| 4 |
[GO] |
2025―Jun―27 |
P107 Association between the COVID-19 vaccination programme and incidence rates of bullous pemphigoid, herpes zoster and urticaria in the UK: an interrupted time series analysis |
Mikolaj Swiderski, Sarah Lewis, Yana Vinogradova, Matthew J Ridd, Zenas Z N Yiu, Antonia Lloyd-Lavery, Vibhore Prasad, Sonia Gran |
| 5 |
[GO] |
2025―Jun―27 |
P147 Exploring the impact of age and deprivation on malignant melanoma diagnoses during the COVID-19 pandemic in England: a national retrospective cohort study |
Lena Ibrahim, Birgitta van Bodegraven, Nick J Levell, Zoe C Venables |
| 6 |
[GO] |
2025―Jun―19 |
Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study |
Mikolaj Swiderski, Sarah Lewis, Yana Vinogradova, Matthew J Ridd, Zenas Z N Yiu, Antonia Lloyd-Lavery, Vibhore Prasad, Sonia Gran |
| 7 |
[GO] |
2024―Dez―10 |
P08 Study on the impact of COVID-19 infection in patients with moderate-to-severe plaque psoriasis on biologics: a tertiary centre experience in India |
|
| 8 |
[GO] |
2024―Dez―10 |
P37 Humoral immunity to mRNA-based COVID-19 vaccines after a booster dose in patients with psoriasis receiving immunomodulatory therapy |
|
| 9 |
[GO] |
2024―Dez―10 |
P114 Deucravacitinib treatment did not affect immune response to SARS-Cov-2 vaccines and infection in patients with plaque psoriasis: results from the Phase 3 POETYK long-term extension trial |
|
| 10 |
[GO] |
2024―Jun―28 |
P076 Risk of psoriatic arthritis and uveitis among patients with psoriasis after COVID-19 infection: a nationwide cohort study |
Tai-Li Chen, Chen-Yi Wu, Wei-Chuen Chang, Chih-Chiang Chen |
| 11 |
[GO] |
2024―Jun―28 |
DP08 Striking post COVID-19 vaccine aseptic pustular folliculitis, a follicular variant of acute generalized exanthematous pustulosis |
Nikesh Patel, Natalie King-Stokes, Jonathan Carter, Richard Carr |
| 12 |
[GO] |
2024―Jun―28 |
BG08 Boosting the cutaneous chronicle of the COVID-19 vaccine: it’s not over yet |
Emily Moon, Chenjing Peng, Anthony Abdullah |
| 13 |
[GO] |
2024―Jun―28 |
BT19 The rising dermatology advice and guidance pandemic: building a workforce group with nationally implantable solutions that led to significant improvements over a 10-week period |
Charankumal Singh Thandi, Jake Moss, Margaret Andrews |
| 14 |
[GO] |
2024―Jun―28 |
O13 42 590 fewer skin tumours diagnosed in England during the 2020 COVID pandemic: greatest reductions in melanoma in situ, stage I melanomas and basal cell carcinomas |
Omsin Srimudkul, Zoe C Venables, Nick J Levell, Khaylen Mistry, Birgitta Van Bodegraven |
| 15 |
[GO] |
2023―Dez―01 |
Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea |
Minji Kim, Yujin Choi, Myeongcheol Lee, Jiseung Kang, So Min Kang, Dong-Geol Lee, Dong Keon Yon |
| 16 |
[GO] |
2023―Okt―27 |
Career advancement for female academic dermatologists: how the pandemic exacerbated inequities, and the path forward |
Ramneek K Dhami, Justin W Ng, Erin L Foster, Emile Latour, Jesse J Keller |
| 17 |
[GO] |
2023―Okt―02 |
Melanoma incidence and COVID-19 lockdowns in the Netherlands |
Philippe Autier |
| 18 |
[GO] |
2023―Aug―25 |
O01 Clinical aspects of psoriasis flares and risk factors for developing a post-infectious flare in children with SARS-CoV-2 infection: data from the Chi-PsoCov registry |
Emmanuel Mahé, Vito di Lernia, Anna Belloni Fortina, Aleksandra Lesiak, Piotr Brzezinski, Zeynep Topkarci, Nikolay Murashkin, Tiago Torres, Helena Vidaurri De La Cruz, Annabel Maruani, Anca Chiriac, Anne-Claire Bursztejn, Juul Van Den Reek, Roman Epishev, Maella Severino-Freire, Maria Akinde, Catalina Luca, Jayakar Thomas, Jinane Zitouni, Tess McPherson, Satveer Mahil, Catherine Smith, Carsten Flohr, Hervé Bachelez |
| 19 |
[GO] |
2023―Aug―25 |
P06 Atopic dermatitis and psoriasis in children, and SARS-CoV-2 infection: different impact of the infection on these dermatoses, and of these dermatoses on the infection? |
Emmanuel Mahé, Jinane Zitouni, Maud Amy de la Breteque |
| 20 |
[GO] |
2023―Jul―18 |
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV2 infection and vaccination |
Rebecca Favaro, Alessandra Formai, Giulia Pavia, Luigi Gargiulo, Jessica Avagliano, Mario Valenti, Paola Facheris, Beatrice Salsano, Roberta V Latorre, Francesco Bellinato, Paolo Gisondi, Alessandra Narcisi, Antonio Costanzo |
| 21 |
[GO] |
2023―Jun―28 |
Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19 |
Min Luo, Changhua Zhu, Jinger Lin, Lihang Lin, Yue Han |
| 22 |
[GO] |
2023―Jun―26 |
BT04 Efficient triaging of advice and guidance referrals using teledermatology via the National Health Service Electronic Referral System platform: reporting positive outcomes from the COVID-19 era |
Anthoula Efstathiadou, Kellen Beck-Sander, Wen Ai Woo, Hywel Cooper, Charles Mitchell |
| 23 |
[GO] |
2023―Jun―26 |
DP07 The effect of the COVID-19 pandemic on the Breslow thickness of melanoma at presentation |
Eva Lau, Joanne Bowers, Katherine Humphris, Louise Binns, Benjamin Walker, Alison Layton |
| 24 |
[GO] |
2023―Jun―26 |
P32 Impact of the COVID-19 pandemic on health equality in malignant melanoma diagnosis |
Kenny Lau, Huan Cheng, Rima Hussain |
| 25 |
[GO] |
2023―Jun―26 |
P15 Progressive papulonodular eruption following COVID-19 infection: a rare diagnosis and review of the literature |
Rhian Sheppeard, Stephanie Austin, Caroline Morgan, Margaret Ashton-Key |
| 26 |
[GO] |
2023―Jun―26 |
P28 Impact of the COVID-19 pandemic on cutaneous squamous cell carcinoma pathology reports in England and its nine regions: 1127 fewer cSCCs reported in 2020 compared with that in 2019 |
James Wall, Zoe Venables, Nick Levell |
| 27 |
[GO] |
2023―Jun―26 |
P09 A case of suspected COVID-19 vaccine-induced antiphospholipid syndrome |
Patrick Bryan, Namor Williams, Geraldine Haebich |
| 28 |
[GO] |
2023―Mai―21 |
Hidradenitis suppurativa patient-reported influences on COVID-19 vaccine acceptance and hesitancy |
Jazzmin C Williams, Raed Alhusayen, Sandra Guilbault, John R Ingram, Michelle A Lowes, Christine A Yannuzzi, Haley B Naik |
| 29 |
[GO] |
2023―Mai―03 |
COVID-19 and the skin, three years on: long term impacts, emerging trends and clinical practice |
Esther E Freeman, Ignacio Garcia-Doval, Luigi Naldi, Rod J Hay |
| 30 |
[GO] |
2023―Apr―20 |
Immunity 6 months after COVID-19 vaccination in patients with psoriasis treated with immunomodulatory drugs |
|
| 31 |
[GO] |
2023―Apr―10 |
Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019 |
Lena S Ibrahim, Zoe C Venables, Sean McPhail, Nick J Levell |
| 32 |
[GO] |
2023―Feb―10 |
Responses to AstraZeneca COVID-19 vaccines in patients with immune-mediated skin diseases |
|
| 33 |
[GO] |
2023―Jan―27 |
Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study |
Amanda Kvist-Hansen, Laura Pérez-Alós, Rownaq Fares Al-Sofi, Line Dam Heftdal, Sebastian Rask Hamm, Dina Leth Møller, Mia Marie Pries-Heje, Kamille Fogh, Cecilie Bo Hansen, Rasmus Bo Hasselbalch, Johannes Roth Madsen, Jose Juan Almagro Armenteros, Ruth Frikke-Schmidt, Linda Hilsted, Erik Sørensen, Sisse Rye Ostrowski, Henning Bundgaard, Susanne Dam Nielsen, Kasper Iversen, Claus Zachariae, Peter Garred, Lone Skov |
| 34 |
[GO] |
2023―Jan―20 |
Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum) |
Laura Adams, Georgina Nakafero, Matthew J Grainge, Tim Card, Christian D Mallen, Jonathan S Nguyen Van-Tam, Hywel C Williams, Abhishek Abhishek |
| 35 |
[GO] |
2023―Jan―20 |
Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey |
Sophia Quirke-McFarlane, John Weinman, Emma S Cook, Zenas Z N Yiu, Nick Dand, Sinead M Langan, Katie Bechman, Teresa Tsakok, Kayleigh J Mason, Helen McAteer, Freya Meynell, Bolaji Coker, Alexandra Vincent, Dominic Urmston, Amber Vesty, Jade Kelly, Camille Lancelot, Lucy Moorhead, Ines A Barbosa, Herve Bachelez, Francesca Capon, Claudia R Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jo Lambert, Luigi Naldi, Lluís Puig, Phyllis Spuls, Tiago Torres, Richard B Warren, Hoseah Waweru, James B Galloway, Christopher E M Griffiths, Jonathan N Barker, Sam Norton, Catherine H Smith, Satveer K Mahil |
| 36 |
[GO] |
2023―Jan―20 |
Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination |
Lluís Puig |
| 37 |
[GO] |
2023―Jan―19 |
Non-adherence to immune-modifying therapies during Covid-19 pandemic: the crucial role of doctor-patient communication to avoid drug discontinuation |
Mario Valenti, Antonio Costanzo |
| 38 |
[GO] |
2023―Jan―08 |
Failure to detect SARS-CoV-2 in the sweat of COVID-19 patients at RNA and protein level |
Thilo Gambichler, Silke Goesmann, Vera Korte, Marina Skrygan, Friederike Harnischfeger, Christina H Scheel, Nazha Hamdani, Heidi Budde, Marcel Sieme, Juergen C Becker, Wolfgang Schmidt |
| 39 |
[GO] |
2022―Aug―16 |
COVID-19 pandemic associated chilblains. More link for SARS-CoV-2 and less evidence for high interferon type-1 systemic response |
Didier Bessis, Sophie Trouillet-Assant, Léo-Paul Secco, Nathalie Bardin, Brigitte Blanc, Véronique Blatière, Christine Chable-Bessia, Christophe Delfour, Céline Girard, Nathalie Gros, Vincent Le Moing, Nicolas Molinari, Valérie Pallure, Amandine Pisoni, Nadia Raison-Peyron, Elisa Reynaud, Émilie Schwob, Rémi Pescarmona, Quentin Samaran, Marjolaine Willems, Thierry Vincent, Mircea T Sofonea, Alexandre Belot, Édouard Tuaillon |
| 40 |
[GO] |
2022―Aug―02 |
Nailfold videocapillaroscopy and serum VEGF in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment |
Yora Mostmans, Vanessa Smith, Maurizio Cutolo, Karin Melsens, Salomé Battist, Asma Benslimane, Francis Corazza, Bertrand Richert, Olivier Michel, Athanassios Kolivras |
| 41 |
[GO] |
2022―Jul―23 |
Cutaneous Manifestations of
SARS-CoV
-2 infection during the Delta and Omicron waves in 348,691
UK
users of the
UK ZOE COVID
Study App |
Alessia Visconti, Benjamin Murray, Niccolò Rossi, Jonathan Wolf, Sebastien Ourselin, Tim D. Spector, Esther E. Freeman, Veronique Bataille, Mario Falchi |
| 42 |
[GO] |
2022―Jul―06 |
P02: Toxic epidermal necrolysis after COVID-19 booster vaccination: is a mixed vaccination schedule a risk? |
|
| 43 |
[GO] |
2022―Jul―06 |
GIRFT01: The long-term costs of COVID-19 for patients with skin cancer: a retrospective single-centre review of multidisciplinary team skin cancer cases and outcomes from 2019 to 2021 |
|
| 44 |
[GO] |
2022―Jul―06 |
P11: Leser-Trélat sign: can it follow COVID-19 infection? |
|
| 45 |
[GO] |
2022―Jul―06 |
RF02: Hospitalization from COVID-19 is most frequently observed in patients with atopic dermatitis treated with systemic corticosteroids, and in particular when systemic corticosteroids are used in combination with another immunomodulatory treatment: lessons from the global SECURE-AD registry |
|
| 46 |
[GO] |
2022―Jul―06 |
GIRFT03: The number needed to treat metric: a further marker of the impact of COVID-19 on malignant melanomas |
|
| 47 |
[GO] |
2022―Jul―06 |
O02: Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform |
|
| 48 |
[GO] |
2022―Jul―06 |
P24: Benzalkonium chloride: a potential emerging allergen in the era of the COVID-19 pandemic |
|
| 49 |
[GO] |
2022―Jul―06 |
P19: Fast-track occupational health dermatology clinic for healthcare workers: trends and burden of occupational dermatoses during the COVID-19 pandemic |
|
| 50 |
[GO] |
2022―Jul―06 |
P49: A comparative analysis of cutaneous squamous cell carcinoma staging before and during the COVID-19 pandemic. |
|
| 51 |
[GO] |
2022―Jul―06 |
GIRFT02: The influence of the COVID-19 pandemic on Breslow thickness and outpatient malignant melanoma service provision in an Irish Dermatology centre |
|
| 52 |
[GO] |
2022―Jul―06 |
P47: Effects of the COVID-19 pandemic on quality of utilization of the 2-week wait skin cancer pathway |
|
| 53 |
[GO] |
2022―Jul―06 |
P42: Clinical, histopathological and dermatoscopic characterization of eruptive pseudoangioma developing after COVID-19 vaccination |
|
| 54 |
[GO] |
2022―Jul―06 |
P29: COVID-19 vaccination and leprosy: a UK hospital-based retrospective cohort study |
|
| 55 |
[GO] |
2022―Jul―06 |
P46: A case series of COVID-19 vaccination and lymphatic dysfunction |
|
| 56 |
[GO] |
2022―Jul―06 |
CPC08: New-onset pemphigus foliaceus following COVID-19 vaccine |
|
| 57 |
[GO] |
2022―Jul―06 |
CPC02: An unusual case of rash secondary to the COVID-19 vaccine is presented with a review of the literature |
|
| 58 |
[GO] |
2022―Jul―06 |
P04: Phototherapy to treat a COVID-19 vaccine reaction |
|
| 59 |
[GO] |
2022―Jul―06 |
CD15: The development of a semi-virtual patch testing service at a university hospital during the
COVID
-19 pandemic |
|
| 60 |
[GO] |
2022―Jul―06 |
BI05: Is a hybrid skin cancer surveillance service for organ transplant recipients feasible? Lessons from the pandemic |
|
| 61 |
[GO] |
2022―Jul―06 |
PA08: Survey of caregiver satisfaction with remote versus face-to-face consultations in a tertiary paediatric dermatology clinic during the
COVID
-19 pandemic |
|
| 62 |
[GO] |
2022―Jul―06 |
H19: Plica polonica: a Polish pandemic |
|
| 63 |
[GO] |
2022―Jul―06 |
BT23: The impact of the
COVID
-19 pandemic and use of teledermatology in specialty training: experience at two
UK
dermatology training centres |
|
| 64 |
[GO] |
2022―Jul―06 |
BT17: A 3-year review of an innovative teledermatology service in paediatric dermatology delivering results in the face of a pandemic backlog |
|
| 65 |
[GO] |
2022―Jul―06 |
DP17: Impact of the
COVID
-19 pandemic on melanoma staging in a Scottish health board |
|
| 66 |
[GO] |
2022―Jul―06 |
BT03 (P47): Effects of the
COVID
-19 pandemic on quality of utilization of the 2-week wait skin cancer pathway |
|
| 67 |
[GO] |
2022―Jul―06 |
BT24: The effect of the
COVID
-19 pandemic on teledermatology usage and practices in a major secondary care centre |
|
| 68 |
[GO] |
2022―Jul―06 |
DS07: Missing melanomas in England during the
COVID
-19 pandemic: 2488 fewer melanoma diagnoses in 2020 than in 2019 |
|
| 69 |
[GO] |
2022―Jul―06 |
H07: A historical review of pandemics with a dermatological perspective |
|
| 70 |
[GO] |
2022―Jun―14 |
Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with Coronavirus Disease 2019: A case series from a large United States healthcare system |
Bethany Cucka, Bianca Biglione, Li Zhou, Elizabeth J. Phillips, Fatima Bassir, Upeka Samarakoon, Renajd Rrapi, Sidharth Chand, Liqin Wang, Santiago Alvarez-Arango, Kimberly G. Blumenthal, Daniela Kroshinsky |
| 71 |
[GO] |
2022―Jun―02 |
Sweet-like syndrome and Multiple COVID-Arm syndrome following COVID-19 vaccines: “Specific” patterns in a series of 192 patients |
Anne-Sophie Darrigade, Bénédicte Oulès, Pierre Sohier, Marie-Laure Jullie, Philippe Moguelet, Annick Barbaud, Angèle Soria, Nicolas Vignier, Bénédicte Lebrun-Vignes, Paola Sanchez-Pena, Olivier Chosidow, Marie Beylot-Barry, Brigitte Milpied, Nicolas Dupin |
| 72 |
[GO] |
2022―Jun―02 |
Pernio and Early SARS-CoV-2 Variants: Natural History of a Prospective Cohort and the Role of Interferon |
Ashley T. Ng, John J. Moon, Olivia R. Steidl, Hailey Bussan, Jennifer M. Tran, George Luong, Aman Nihal, Meaghan Kenfield, Justin Frere, Benjamin R. tenOever, Ana C. Costa da Silva, Jacqueline W. Mays, Edward W. Cowen, Beth A. Drolet, Anne Marie Singh, Lisa M. Arkin |
| 73 |
[GO] |
2022―Mai―25 |
Heterogeneity of reports about the impact of the
COVID
-19 pandemic on melanoma diagnosis |
Francesco Ricci, Damiano Abeni |
| 74 |
[GO] |
2022―Feb―01 |
Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey |
Katie Bechman, Emma S. Cook, Nick Dand, Zenas Z.N. Yiu, Teresa Tsakok, Freya Meynell, Bolaji Coker, Alexandra Vincent, Herve Bachelez, Ines Barbosa, Matthew A. Brown, Francesca Capon, Claudia R. Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jade Kelly, Jo Lambert, Camille Lancelot, Sinead M. Langan, K.J. Mason, Helen McAteer, Lucy Moorhead, Luigi Naldi, Sam Norton, Lluís Puig, Phyllis I. Spuls, Tiago Torres, Dominic Urmston, Amber Vesty, Richard B. Warren, Hoseah Waweru, John Weinman, Christopher M. Griffiths, Jonathan N. Barker, Catherine H. Smith, James B. Galloway, Satveer K. Mahil |
| 75 |
[GO] |
2022―Jan―27 |
Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients |
Haig Pakhchanian, Rahul Raiker, Melanie Wolf, Shannon C. Trotter |
| 76 |
[GO] |
2022―Jan―06 |
Do treatments for psoriasis increase the risk of hospital admission or death caused by COVID-19 infections? |
|
| 77 |
[GO] |
2022―Jan―06 |
Varied skin reactions after COVID-19 vaccination |
|
| 78 |
[GO] |
2021―Dez―17 |
Chilblain-like lesions during the COVID-19 outbreak |
|
| 79 |
[GO] |
2021―Nov―29 |
COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation |
M. Kasperkiewicz, R. Strong, K. Mead, M. Yale, D. Zillikens, D.T. Woodley, A. Recke |
| 80 |
[GO] |
2021―Nov―25 |
Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine |
T. Žagar, N. Hlača, I. Brajac, L. Prpić-Massari, S. Peternel, M. Kaštelan |
| 81 |
[GO] |
2021―Nov―13 |
Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies |
T. Gambichler, N. Hamdani, H. Budde, M. Sieme, M. Skrygan, L. Scholl, H. Dickel, B. Behle, N. Ganjuur, C. Scheel, N. Abu Rached, L. Ocker, R. Stranzenbach, M. Doerler, L. Pfeiffer, J.C. Becker |
| 82 |
[GO] |
2021―Nov―08 |
Should we look beyond the interferon signature in chilblain-like lesions associated with COVID-19? |
S.M. Pilkington, R.E.B. Watson |
| 83 |
[GO] |
2021―Nov―02 |
Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic |
S. Cazzaniga, L. Naldi |
| 84 |
[GO] |
2021―Nov―02 |
COVID-19 vaccines and skin manifestations |
V. Bataille, S. Puig |
| 85 |
[GO] |
2021―Nov―02 |
Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination |
T. Gambichler, C. Krogias, I. Tischoff, A. Tannapfel, R. Gold, L. Susok |
| 86 |
[GO] |
2021―Okt―08 |
Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak |
L. Frumholtz, J.-D. Bouaziz, M. Battistella, J. Hadjadj, R. Chocron, D. Bengoufa, H. Le Buanec, L. Barnabei, S. Meynier, O. Schwartz, L. Grzelak, N. Smith, B. Charbit, D. Duffy, N. Yatim, A. Calugareanu, A. Philippe, C.L. Guerin, B. Joly, V. Siguret, L. Jaume, H. Bachelez, M. Bagot, F. Rieux-Laucat, S. Maylin, J. Legoff, C. Delaugerre, N. Gendron, D.M. Smadja, C. Cassius |
| 87 |
[GO] |
2021―Okt―06 |
Occupational dermatoses during the second COVID-19 pandemic wave: a UK prospective study of 805 healthcare workers |
J. M. Gao, R. Goiriz, S. Rajpopat, P. Goldsmith |
| 88 |
[GO] |
2021―Sep―29 |
A case of COVID-19 vaccination-associated
forme fruste
purpura fulminans |
J. Griss, S. Eichinger, S. Winkler, W. Weninger, P. Petzelbauer |
| 89 |
[GO] |
2021―Aug―24 |
Not relevant responses in the era of Covid-19 - are we underestimating dermatology life quality index values? |
N. Kearney, R. Hambly, A. Alsharqi, B. Kirby |
| 90 |
[GO] |
2021―Aug―16 |
Sunlight separately from vitamin D is associated with a lower risk of death from COVID-19 |
|
| 91 |
[GO] |
2021―Jul―26 |
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1,326,312 patients in France |
L. Penso, R. Dray-Spira, A. Weill, M. Zureik, E. Sbidian |
| 92 |
[GO] |
2021―Jul―14 |
Analysis of T cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in chilblain-like lesions patients during the COVID-19 pandemic |
C. Cassius, M. Merandet, L. Frumholtz, D. Bergerat, A. Samri, C. Grolleau, L. Grzelak, O. Schwartz, N. Yatim, P. Moghadam, L. Jaume, M. Bagot, J. Legoff, C. Delaugerre, J.-D. Bouaziz, H. Le Buanec |
| 93 |
[GO] |
2021―Jul―13 |
Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases |
A. Català, C. Muñoz-Santos, C. Galván-Casas, M. Roncero Riesco, D. Revilla Nebreda, A. Solá-Truyols, P. Giavedoni, M. Llamas-Velasco, C. González-Cruz, X. Cubiró, R. Ruíz-Villaverde, S. Gómez-Armayones, M.P. Gil Mateo, D. Pesqué, O. Marcantonio, D. Fernández-Nieto, J. Romaní, N. Iglesias Pena, L. Carnero Gonzalez, J. Tercedor-Sanchez, G. Carretero, T. Masat-Ticó, P. Rodríguez-Jiménez, A.M. Gimenez-Arnau, M. Utrera-Busquets, E. Vargas Laguna, A.G. Angulo Menéndez, E. San Juan Lasser, M. Iglesias-Sancho, L. Alonso Naranjo, I. Hiltun, E. Cutillas Marco, I. Polimon Olabarrieta, S. Marinero Escobedo, X. García-Navarro, M.J. Calderón Gutiérrez, G. Baeza-Hernández, L. Bou Camps, T. Toledo-Pastrana, A. Guilabert |
| 94 |
[GO] |
2021―Jul―06 |
GIRFT06: Dermatology high-cost drug management: pharmacists getting it right first time in COVID-19 |
|
| 95 |
[GO] |
2021―Jul―06 |
DS26: COVID-19 and reduced detection of malignant melanoma in secondary dermatology services |
|
| 96 |
[GO] |
2021―Jul―06 |
DT04: Pandemic placement: delivering the dermatology undergraduate curriculum at a UK medical school during the COVID-19 crisis |
|
| 97 |
[GO] |
2021―Jul―06 |
BT10: Medical education in the COVID-19 era: a remote dermatology attachment |
|
| 98 |
[GO] |
2021―Jul―06 |
DS06: Contending with COVID-19 in a Mohs micrographic surgery service |
|
| 99 |
[GO] |
2021―Jul―06 |
P19: Cutaneous manifestations of COVID-19 in the UK: a registry of digital submissions from interdisciplinary healthcare professionals |
|
| 100 |
[GO] |
2021―Jul―06 |
DP16: Severe, ulcerative cold panniculitis following COVID-19 infection |
|
| 101 |
[GO] |
2021―Jul―06 |
DP08: Leprosy unmasked by COVID-19 infection: a new diagnosis of leprosy with development of type 1 reversal reaction |
|
| 102 |
[GO] |
2021―Jul―06 |
DS25: Pandemic pressures: the impact of COVID-19 on the 2-week-wait service at a regional skin oncology centre |
|
| 103 |
[GO] |
2021―Jul―06 |
P28: The effects of COVID-19 on undergraduate dermatology training: a qualitative study |
|
| 104 |
[GO] |
2021―Jul―06 |
BT19: The use of a novel teledermatology/teledermoscopy service to maintain a dermatology cancer service in the midst of the COVID-19 pandemic |
|
| 105 |
[GO] |
2021―Jul―06 |
BT18: A new era for teledermatology in the COVID-19 pandemic |
|
| 106 |
[GO] |
2021―Jul―06 |
BT16: Disaster-recovery modelling to shape services: a dermatology helpline as a telemedicine intervention during the initial surge of the COVID-19 pandemic |
|
| 107 |
[GO] |
2021―Jul―06 |
PD11: Access to phototherapy during the COVID-19 pandemic |
|
| 108 |
[GO] |
2021―Jul―06 |
BT14: Exploring the feasibility of a remote acne service: a report of a pilot study using the MySkinSelfie platform during the COVID-19 pandemic |
|
| 109 |
[GO] |
2021―Jul―06 |
BT09: Standard of patient-sent images in teledermatology 2-week-wait skin cancer clinics during the COVID-19 pandemic |
|
| 110 |
[GO] |
2021―Jul―06 |
BI08: Remote management of immunotherapy-induced bullous pemphigoid during the COVID-19 pandemic |
|
| 111 |
[GO] |
2021―Jul―06 |
DS14: Experience of using a scar-assessment tool to evaluate scars after Mohs surgery via virtual consultation during the COVID-19 pandemic |
|
| 112 |
[GO] |
2021―Jul―06 |
P57: Surprising trends in the detection of cutaneous malignancy during the COVID-19 pandemic |
|
| 113 |
[GO] |
2021―Jul―06 |
BT15: Evaluating paediatric dermatology telephone clinics during the COVID-19 pandemic in a UK cohort: a prospective study |
|
| 114 |
[GO] |
2021―Jul―06 |
DS23: A multicentre qualitative study of patients’ experience of skin surgery during the COVID-19 pandemic in the UK |
|
| 115 |
[GO] |
2021―Jul―06 |
DT07: The impact of the COVID-19 pandemic on dermatology ST3 application preparation: a national survey of junior doctors in the UK |
|
| 116 |
[GO] |
2021―Jul―06 |
BI07: The effect of the COVID-19 pandemic on immunosuppressed patients undergoing skin surveillance |
|
| 117 |
[GO] |
2021―Jul―06 |
O01: The impact of the COVID-19 pandemic on people with psoriasis: findings from a global patient-reported registry |
|
| 118 |
[GO] |
2021―Jul―06 |
P25: The impact of the second wave of the COVID-19 pandemic on the quality of life of patients with skin cancer |
|
| 119 |
[GO] |
2021―Jul―06 |
CD08: Occupational dermatoses during the second COVID-19 pandemic wave: an audit of 401 healthcare workers |
|
| 120 |
[GO] |
2021―Jul―06 |
P38: Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting |
|
| 121 |
[GO] |
2021―Jul―06 |
PS06 (P38): Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting |
|
| 122 |
[GO] |
2021―Jul―06 |
BT12: The environmental impact of teledermatology in the COVID-19 pandemic: a silver lining |
|
| 123 |
[GO] |
2021―Jul―06 |
CD07: A survey of the incidence of skin problems in a cohort of hospital staff during the COVID-19 pandemic: can this help plan future services? |
|
| 124 |
[GO] |
2021―Jul―06 |
DT03: Diversifying educational resources during the COVID-19 pandemic: delivering educational dermatology podcasts and webinars for healthcare professionals |
|
| 125 |
[GO] |
2021―Jul―06 |
BT04: A new virtual inpatient dermatology electronic referral service: a timely answer to reducing cross-contamination during the COVID-19 pandemic? |
|
| 126 |
[GO] |
2021―Jul―06 |
DT02: What has been the impact of COVID-19 redeployment on dermatology trainees’ professional identity? An interpretative phenomenological study |
|
| 127 |
[GO] |
2021―Jul―06 |
P21: Practising dermatology in the era of COVID-19: a tertiary centre’s experience of adapting to change |
|
| 128 |
[GO] |
2021―Jul―06 |
PD14: Treating field cancerization in a time of COVID-19: daylight photodynamic therapy is effective, socially distant and satisfactory to our most vulnerable patients |
|
| 129 |
[GO] |
2021―Jul―06 |
P46: Occupational dermatoses during COVID-19: effect on work and wellbeing |
|
| 130 |
[GO] |
2021―Jul―06 |
P62: An increase in Breslow thickness: coronavirus or coincidence? |
|
| 131 |
[GO] |
2021―Jul―06 |
PD05: Skin safety and efficacy of filtered far ultraviolet C for SARS-CoV-2 inactivation |
|
| 132 |
[GO] |
2021―Jul―06 |
CD09: A review of semi-virtual patch testing during the SARS-CoV-2 pandemic: practicalities and patient experience |
|
| 133 |
[GO] |
2021―Jul―06 |
Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination |
T. Gambichler, S. Boms, S. Hessam, I. Tischoff, A. Tannapfel, T. Lüttringhaus, J. Beckman, R. Stranzenbach |
| 134 |
[GO] |
2021―Jul―06 |
P24: Dermatology medical student history taking via the telephone: a way to minimize disruption to medical education, particularly during a pandemic |
|
| 135 |
[GO] |
2021―Jul―06 |
P73: A novel approach to systemic monitoring in a pandemic |
|
| 136 |
[GO] |
2021―Jul―05 |
Yet another benefit from sunlight in the fight against COVID-19? |
R.L. McKenzie, J.B. Liley |
| 137 |
[GO] |
2021―Jul―03 |
在 2019 年新型冠状病毒疾病 (COVID-19) 疫情期间, 银屑病或关节病患者的隔离因治疗类型而异 |
|
| 138 |
[GO] |
2021―Jul―03 |
Shielding behaviour in people with psoriasis or a joint condition during the COVID-19 pandemic differs by treatment type |
|
| 139 |
[GO] |
2021―Jun―15 |
Relapse of chilblain-like lesions during the second COVID-19 pandemic wave: a cohort follow-up |
T. Hubiche, F. Le Duff, E. Fontas, J. Rapp, C. Chiaverini, T. Passeron |
| 140 |
[GO] |
2021―Jun―11 |
Kawasaki-like Multisystem Inflammatory Syndrome Associated with Coronavirus disease 2019 in an Adult: A case report |
R. Dabas, G. Varadaraj, S. Sandhu, A. Bhatnagar, R. Pal |
| 141 |
[GO] |
2021―Jun―09 |
COVID-19 outcomes in patients with autoimmune blistering disease |
E. Hwang, M.M. Tomayko |
| 142 |
[GO] |
2021―Mai―25 |
COVID-19-associated multisystem inflammatory syndrome in adults with Kawasaki disease-like cutaneous manifestations |
M. Razmi T, T.P. Afra, T.P. Mohammed, P.T.M. Ashik, E. Sukesh |
| 143 |
[GO] |
2021―Mai―20 |
Forewarned is Forearmed:
chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health |
W.H. Bermingham, M.R. Ardern-Jones, A.P. Huissoon, M.T. Krishna |
| 144 |
[GO] |
2021―Mai―19 |
Skin checks and skin cancer diagnosis in Australian general practice before and during the COVID pandemic, 2011-2020 |
J. Roseleur, D.A. Gonzalez-Chica, J. Emery, N.P. Stocks |
| 145 |
[GO] |
2021―Mai―17 |
Rarity of cutaneous findings among asymptomatic to mildly symptomatic COVID-19 patients admitted to a COVID Care facility in Delhi, India: An observational study |
A. Khurana, A. Mittal, R. Jain, A. Mishra, S.R. Mathachan |
| 146 |
[GO] |
2021―Mai―13 |
Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease |
A. Al-Janabi, Z. Littlewood, C.E.M. Griffiths, H.J.A. Hunter, H. Chinoy, C. Moriarty, Z.Z.N. Yiu, R.B. Warren |
| 147 |
[GO] |
2021―Mai―07 |
SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study |
C. Nguyen, K. Yale, F. Casale, A. Ghigi, K. Zheng, J.I. Silverberg, N.A. Mesinkovska |
| 148 |
[GO] |
2021―Mai―06 |
Psoriasis, COVID-19 and shielding |
G. Becher, A.D. Burden |
| 149 |
[GO] |
2021―Mai―05 |
Diagnosis of COVID-19 using skin rashes |
|
| 150 |
[GO] |
2021―Mai―03 |
The impact of the COVID-19 pandemic on skin cancer incidence and treatment in England, 2020 |
Z.C. Venables, S. Ahmed, T. Bleiker, J. Broggio, M. Kwiatkowska, N.J. Levell, G.W.M. Millington, L. Paley, E. Payne, C. Proby, S. Vernon, S. McPhail |
| 151 |
[GO] |
2021―Apr―27 |
Chilblain lesions after COVID-19 mRNA vaccine |
A. Pileri, A. Guglielmo, B. Raone, A. Patrizi |
| 152 |
[GO] |
2021―Apr―27 |
Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination |
A.M. Carballido Vázquez, B. Morgado |
| 153 |
[GO] |
2021―Apr―24 |
Pernio after COVID-19 Vaccination |
S. Lopez, P. Vakharia, T. Vandergriff, E.E. Freeman, R. Vasquez |
| 154 |
[GO] |
2021―Apr―10 |
Outcomes of COVID-19 in Patients with Skin Cancer |
R. Raiker, H. Pakhchanian, A. Hussain, M. Deng |
| 155 |
[GO] |
2021―Apr―09 |
Ultraviolet A Radiation and COVID-19 Deaths in the USA with replication studies in England and Italy |
M. Cherrie, T. Clemens, C. Colandrea, Z. Feng, D.J. Webb, R.B. Weller, C. Dibben |
| 156 |
[GO] |
2021―Mrz―18 |
Recurrence of chilblains during a second contact with SARS-CoV-2: a case report |
S. Maanaoui, F. Salez, O. Carpentier |
| 157 |
[GO] |
2021―Mrz―17 |
Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study |
Z.Z.N. Yiu, G. Harding, C.E.M. Griffiths, R.B. Warren, E. McMullen, H.J.A. Hunter |
| 158 |
[GO] |
2021―Mrz―04 |
The skin as a target for SARS-CoV-2 infection: exploiting the web for suitable data |
L. Naldi |
| 159 |
[GO] |
2021―Mrz―03 |
Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic |
E.E. Freeman, D.E. McMahon, J.B. Lipoff, M. Rosenbach, S.R. Desai, M. Fassett, L.E. French, H.W. Lim, G.J. Hruza, L.P. Fox |
| 160 |
[GO] |
2021―Feb―20 |
Intention of COVID-19 vaccination among psoriatic patients compared to immunosuppressed patients with other skin diseases and factors influencing their decision |
E. Sotiriou, K. Bakirtzi, I. Papadimitriou, E. Paschou, E. Vakirlis, A. Lallas, D. Ioannides |
| 161 |
[GO] |
2021―Feb―08 |
与 COVID-19 相关的皮肤疾病以及相关生物制剂 |
|
| 162 |
[GO] |
2021―Feb―08 |
Association of COVID-19 with skin diseases and relevant biologics |
|
| 163 |
[GO] |
2021―Jan―29 |
SARS-CoV-2 Spike Protein Positivity in Pityriasis Rosea-like and Urticaria-like Rashes of COVID-19 |
E. Welsh, J.A. Cardenas-de la Garza, A. Cuellar-Barboza, R. Franco-Marquez, R.I. Arvizu-Rivera |
| 164 |
[GO] |
2021―Jan―17 |
Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality? |
C. Bernigaud, D. Guillemot, A. Ahmed-Belkacem, L. Grimaldi-Bensouda, A. Lespine, F. Berry, L. Softic, C. Chenost, G. Do-Pham, B. Giraudeau, S. Fourati, O. Chosidow |
| 165 |
[GO] |
2021―Jan―15 |
Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection |
A. Visconti, V. Bataille, N. Rossi, J. Kluk, R. Murphy, S. Puig, R. Nambi, R.C.E. Bowyer, B. Murray, A. Bournot, J. Wolf, S. Ourselin, C.J. Steves, T.D. Spector, M. Falchi |
| 166 |
[GO] |
2021―Jan―14 |
COVID-19-associated cutaneous manifestations: does HHV-6 play an etiological role? |
I. Abadías-Granado, A. Navarro-Bielsa, A.M. Morales-Callaghan, L. Roc, C.C. Suso-Estívalez, M. Povar-Echeverría, Y. Gilaberte |
| 167 |
[GO] |
2021―Jan―10 |
COVID-19 related dermatosis in November 2019. Could this case be Italy’s patient zero? |
R. Gianotti, M. Barberis, G. Fellegara, C. Galván-Casas, E. Gianotti |
| 168 |
[GO] |
2020―Dez―24 |
Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey |
S.K. Mahil, M. Yates, S.M. Langan, Z.Z.N. Yiu, T. Tsakok, N. Dand, K.J. Mason, H. McAteer, F. Meynell, B. Coker, A. Vincent, D. Urmston, A. Vesty, J. Kelly, C. Lancelot, L. Moorhead, H. Bachelez, I.N. Bruce, F. Capon, C.R. Contreras, A.P. Cope, C. De La Cruz, P. Di Meglio, P. Gisondi, K. Hyrich, D. Jullien, J. Lambert, H. Marzo-Ortega, I. McKinnes, L. Naldi, S. Norton, L. Puig, R. Sengupta, P. Spuls, T Torres, R.B. Warren, H. Waweru, J. Weinman, C.M. Griffiths, J.N. Barker, M.A. Brown, J.B. Galloway, C.H. Smith |
| 169 |
[GO] |
2020―Dez―16 |
SARS-CoV-2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions: reply from the authors |
I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo |
| 170 |
[GO] |
2020―Dez―10 |
Response to Tembhre et al.: ‘Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2’ |
J.R. Gehlhausen, C.J. Ko, W. Damsky |
| 171 |
[GO] |
2020―Dez―04 |
Association of skin diseases, biological treatment and COVID-19 during the first wave of the pandemic |
M.A. Descalzo, I. Garcia-Doval |
| 172 |
[GO] |
2020―Nov―29 |
Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window |
D. Bessis |
| 173 |
[GO] |
2020―Nov―06 |
Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2 |
M.K. Tembhre, A.S. Parihar, V.K. Sharma, S. Imran, N. Bhari, R. Lakshmy, A. Bhalla |
| 174 |
[GO] |
2020―Nov―05 |
Response to “Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic” |
G. Murray, D. Roche, A. Ridge, C. Hackett, A.M. Tobin |
| 175 |
[GO] |
2020―Nov―03 |
Oral vesiculobullous lesions as an early sign of COVID-19: immunohistochemical detection of SARS-CoV-2 spike protein |
C.D. Soares, A. Mosqueda-Taylor, M.G.F. Carvalho, O.P. Almeida |
| 176 |
[GO] |
2020―Nov―02 |
在 COVID-19 疫情期间观察到的大多数冻疮与 COVID-19 感染无关 |
|
| 177 |
[GO] |
2020―Nov―02 |
Most chilblains observed during the COVID-19 outbreak are not linked to COVID-19 infection |
|
| 178 |
[GO] |
2020―Okt―28 |
Occupational dermatoses during the Covid-19 pandemic: a multicentre audit in the UK and Ireland |
H. O’Neill, I. Narang, D.A. Buckley, T.A. Phillips, C.G. Bertram, T.O. Bleiker, M.M.U. Chowdhury, S.M. Cooper, S. Abdul Ghaffar, G.A. Johnston, L.F. Kiely, J.E. Sansom, N. Stone, D.A. Thompson, P. Banerjee |
| 179 |
[GO] |
2020―Okt―26 |
Prurigo pigmentosa and new-onset type 1 diabetes in a black female patient testing positive for SARS-CoV-2 IgG |
K.M. Derrick, D.R. Mazori, E.R. Heilman, S.A. Glick |
| 180 |
[GO] |
2020―Okt―05 |
SARS-CoV-2 导致冠状病毒脚趾 |
|
| 181 |
[GO] |
2020―Okt―05 |
SARS-CoV-2 causes Covid Toes |
|
| 182 |
[GO] |
2020―Okt―01 |
SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions: reply from authors |
I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo |
| 183 |
[GO] |
2020―Okt―01 |
SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions |
J.K. Brealey, S.E. Miller |
| 184 |
[GO] |
2020―Sep―25 |
Response to ‘No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain’. Reply from the authors |
D. Caselli, M. Chironna, D. Loconsole, M. Aricò |
| 185 |
[GO] |
2020―Sep―24 |
Prevalence of mucocutaneous manifestations, oral and palmoplantar findings in 666 patients with COVID-19 in a field hospital in Spain |
A. Nuno-Gonzalez, P. Martin-Carrillo, K. Magaletsky, M.D. Martin Rios, C. Herranz Mañas, J. Artigas Almazan, G. García Casasola, E. Perez Castro, A. Gallego Arenas, A. Mayor Ibarguren, M. Feito Rodríguez, B. Lozano Masdemont, M. Beato, E. Ruiz Bravo, P. Oliver, M.D. Montero Vega, P. Herranz Pinto |
| 186 |
[GO] |
2020―Sep―03 |
A review of studies into skin symptoms of COVID-19 |
|
| 187 |
[GO] |
2020―Sep―03 |
COVID-19 皮肤症状研究综述 |
|
| 188 |
[GO] |
2020―Sep―02 |
Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea |
S.I. Cho, Y.E. Kim, S.J. Jo |
| 189 |
[GO] |
2020―Sep―01 |
COVID-19 Session |
|
| 190 |
[GO] |
2020―Sep―01 |
Illuminating, through immunohistochemistry, the link between SARS-CoV-2 and pernio (chilblains) |
D.A. Wetter |
| 191 |
[GO] |
2020―Aug―31 |
Paucity of COVID-19 Dermatology Literature from Low- and Middle-Income Countries |
R.S. Pendse, B.L. Schwartz, J.L. Jia, E.E. Bailey |
| 192 |
[GO] |
2020―Aug―28 |
COVID-19 in hidradenitis suppurativa patients |
X.T. Lima, M.A. Cueva, M.B. Alora |
| 193 |
[GO] |
2020―Aug―28 |
Response to “No evidence of SARS-CoV-2 infection by PCR or serology in children with pseudochilblain” |
S. Recalcati, S. Tonolo, F. Luzzaro, F. Fantini |
| 194 |
[GO] |
2020―Aug―15 |
Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned |
M. Baeck, D. Hoton, L. Marot, A. Herman |
| 195 |
[GO] |
2020―Aug―15 |
Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned: reply from authors |
I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez-Peralto, L. Requena, A. Torrelo |
| 196 |
[GO] |
2020―Aug―13 |
Co-Reactivation of Human Herpesvirus alpha Subfamily (HSV Ⅰ and VZV) in Critically Ill Patient with COVID-19 |
R. Xu, Y. Zhou, L. Cai, L. Wang, J. Han, X. Yang, J. Chen, J. Chen, C. Ma, L. Shen |
| 197 |
[GO] |
2020―Aug―13 |
Occupational Dermatology in the time of the Covid-19 pandemic: A report of experience from London and Manchester, United Kingdom |
F.J. Ferguson, G. Street, L. Cunningham, I.R. White, J.P. McFadden, J. Williams |
| 198 |
[GO] |
2020―Aug―13 |
Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains |
G. Battesti, V. Descamps Vincent |
| 199 |
[GO] |
2020―Aug―13 |
Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains: reply from authors |
L. Le Cleach, S. Fourati, E. Sbidian, M. Beylot-Barry |
| 200 |
[GO] |
2020―Jul―31 |
Cutaneous signs in SARS CoV-2 infection: A plea for more rigorous peer-review in the time of COVID-19 |
H. Kittler, P. Tschandl, W. Weninger |
| 201 |
[GO] |
2020―Jul―23 |
A Very Peculiar Practice: Dermatology in the era of Covid-19 |
S. Walsh, D. Creamer |
| 202 |
[GO] |
2020―Jul―22 |
The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series |
C. Magro, J.J. Mulvey, J. Laurence, S. Sanders, N. Crowson, M. Grossman, J. Harp, G. Nuovo |
| 203 |
[GO] |
2020―Jul―22 |
High incidence of hand eczema in Danish school children following intensive hand hygiene during the COVID-19 pandemic - a nationwide questionnaire study |
A.B. Simonsen, I.F. Ruge, A.S. Q꫞, J.D. Johansen, J.P. Thyssen, C. Zachariae |
| 204 |
[GO] |
2020―Jul―06 |
Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on PCR and serology testing |
L. Le Cleach, L. Dousset, H. Assier, S. Fourati, S. Barbarot, C. Boulard, C. Bourseau Quetier, L. Cambon, C. Cazanave, A. Colin, E. Kostrzewa, C. Lesort, A. Levy Roy, F. Lombart, J. Marco-Bonnet, J.B. Monfort, M. Samimi, M. Tardieu, P. Wolkenstein, E. Sbidian, M. Beylot-Barry |
| 205 |
[GO] |
2020―Jul―02 |
Identificadas las principales manifestaciones en la piel de la COVID-19 |
|
| 206 |
[GO] |
2020―Jul―02 |
COVID-19 确诊患者的五种常见皮肤表现 |
|
| 207 |
[GO] |
2020―Jul―02 |
Response to: “Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases”: Vesicular eruption in COVID-19 - to exclude varicella |
S.Y.D. Lim, H.L. Tey |
| 208 |
[GO] |
2020―Jul―02 |
“Vesicular eruption in COVID-19 - to exclude varicella”: reply from the authors |
A. Català, C. Galván Casas, G. Carretero Hernández, I. García-Doval |
| 209 |
[GO] |
2020―Jul―02 |
Five common skin manifestations of COVID-19 identified |
|
| 210 |
[GO] |
2020―Jul―02 |
Chilblain-like lesions during COVID-19 pandemic: a serological study on a case series |
L. Rizzoli, L. Collini, M. Magnano, S. Termine, R. Barcelli, S.D. Infusino, P. Bauer, G. Rech, C. R. Girardelli, R. Balestri |
| 211 |
[GO] |
2020―Jul―02 |
No evidence of SARS-Cov-2 infection by PCR or serology in children with pseudochilblain |
D. Caselli, M. Chironna, D. Loconsole, L. Nigri, F. Mazzotta, D. Bonamonte, M. Aricò |
| 212 |
[GO] |
2020―Jun―29 |
Global Hidradenitis Suppurativa COVID-19 Registry: A Registry to Inform Data-Driven Management Practices |
H.B. Naik, R. Alhusayen, J. Frew, S. Guilbault, J.R. Ingram, M.A. Lowes, A.V. Marzano, M. Paul, B. Villumsen, C.A. Yannuzzi |
| 213 |
[GO] |
2020―Jun―25 |
COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a PCR-negative patient |
C. Santonja, F. Heras, L. Núñez, L. Requena |
| 214 |
[GO] |
2020―Jun―22 |
Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from authors |
C. Galván-Casas, A. Catalá, G. Carretero Hernández, I. Garcia-Doval |
| 215 |
[GO] |
2020―Jun―20 |
SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases |
I. Colmenero, C. Santonja, M. Alonso-Riaño, L. Noguera-Morel, A. Hernández-Martín, D. Andina, T. Wiesner, J.L. Rodríguez-Peralto, L. Requena, A. Torrelo |
| 216 |
[GO] |
2020―Jun―17 |
SARS-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from the authors |
C. Galván Casas, A. Català, G. Carretero Hernández, I. García-Doval |
| 217 |
[GO] |
2020―Jun―15 |
Risk of infections in psoriasis. A lesson to learn during the
SARS
-CoV-2 pandemic |
L. Naldi |
| 218 |
[GO] |
2020―Jun―13 |
Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations |
F. Drago, G. Ciccarese, A. Rebora, S.I. Muzic, A. Parodi |
| 219 |
[GO] |
2020―Jun―05 |
Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic |
C.H. Earnshaw, H.J.A. Hunter, E. McMullen, C.E.M. Griffiths, R.B. Warren |
| 220 |
[GO] |
2020―Jun―01 |
Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy |
A. Carugno, P. Sena, F. Raponi, E. Robustelli Test, P. Vezzoli |
| 221 |
[GO] |
2020―Jun―01 |
Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue |
A.V. Marzano, N. Cassano, G. Genovese, C. Moltrasio, G.A. Vena |
| 222 |
[GO] |
2020―Jun―01 |
Emergency management of 2019 novel coronavirus: implications for the dermatology department |
J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man |
| 223 |
[GO] |
2020―Mai―29 |
Absence of Skin of Colour Images in Publications of COVID-19 Skin Manifestations |
J.C. Lester, J.L. Jia, L. Zhang, G.A. Okoye, E. Linos |
| 224 |
[GO] |
2020―Mai―29 |
Virtual melanoma checks during a pandemic |
M. Janda, S.M. Swetter, C. Horsham, H.P. Soyer |
| 225 |
[GO] |
2020―Mai―27 |
Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection |
M. Hughes, S. Rogers, G. Lepri, C. Bruni, M. Matucci-Cerinic |
| 226 |
[GO] |
2020―Mai―14 |
Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient |
M. Llamas-Velasco, P. Muñoz-Hernández, J. Lázaro-González, A. Reolid-Pérez, B. Abad-Santamaría, J. Fraga, E. Daudén-Tello |
| 227 |
[GO] |
2020―Apr―30 |
Cutaneous lesions in a patient with COVID-19: are they related? |
B. Ahouach, S. Harant, A. Ullmer, P. Martres, E. Bégon, L. Blum, O. Tess, C. Bachmeyer |
| 228 |
[GO] |
2020―Apr―29 |
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic |
S.K. Mahil, Z.Z.N. Yiu, K.J. Mason, N. Dand, B. Coker, D. Wall, G. Fletcher, A. Bosma, F. Capon, L. Iversen, S.M. Langan, P. Di Meglio, A. Musters, D. Prieto-Merino, T. Tsakok, R.B. Warren, C. Flohr, P. Spuls, C.E.M. Griffiths, J. Barker, A.D Irvine, C.H. Smith |
| 229 |
[GO] |
2020―Apr―29 |
Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases |
C. Galván Casas, A. Català, G. Carretero Hernández, P. Rodríguez-Jiménez, D. Fernández Nieto, A. Rodríguez-Villa Lario, I. Navarro Fernández, R. Ruiz-Villaverde, D. Falkenhain, M. Llamas Velasco, J. García-Gavín, O. Baniandrés, C. González-Cruz, V. Morillas-Lahuerta, X. Cubiró, I. Figueras Nart, G. Selda-Enriquez, J. Romaní, X. Fustà-Novell, A. Melian-Olivera, M. Roncero Riesco, P. Burgos-Blasco, J. Sola Ortigosa, M. Feito Rodriguez, I. García-Doval |
| 230 |
[GO] |
2020―Apr―28 |
The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience |
P. Gisondi, P. Facheris, P. Dapavo, S. Piaserico, A. Conti, L. Naldi, S. Cazzaniga, P. Malagoli, A. Costanzo |
| 231 |
[GO] |
2020―Apr―17 |
Phototherapeutic approach to dermatological patients during the 2019 Coronavirus pandemic: Real-life Data from the Italian Red Zone |
A. Pacifico, M. Ardigò, P. Frascione, G. Damiani, A. Morrone |
| 232 |
[GO] |
2020―Apr―07 |
Adverse Skin Reactions Among Healthcare Workers During the Coronavirus Disease 2019 Outbreak: A Survey in Wuhan and Its Surrounding Regions |
P. Lin, S. Zhu, Y. Huang, L. Li, J. Tao, T. Lei, J. Song, D. Liu, L. Chen, Y. Shi, S. Jiang, Q. Liu, J. Xie, H. Chen, Y. Duan, Y. Xia, Y. Zhou, Y. Mei, X. Zhou, J. Wu, M. Fang, Z. Meng, H. Li |
| 233 |
[GO] |
2020―Mrz―06 |
Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department |
J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man |
